Cargando…

Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS

Amyotrophic lateral sclerosis (ALS) is a devastating disorder in which motor neurons degenerate, the causes of which remain unclear. In particular, the basis for selective vulnerability of spinal motor neurons (sMNs) and resistance of ocular motor neurons (oMNs) to degeneration in ALS has yet to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hojae, Lee, Jae Jin, Park, Na Young, Dubey, Sandeep Kumar, Kim, Taeyong, Ruan, Kai, Lim, Su Bin, Park, Seong-Hyun, Ha, Shinwon, Kovlyagina, Irina, Kim, Kyung-tai, Kim, Seongjun, Oh, Yohan, Kim, Hyesoo, Kang, Sung-Ung, Song, Mi-Ryoung, Lloyd, Thomas E., Maragakis, Nicholas J., Hong, Young Bin, Eoh, Hyungjin, Lee, Gabsang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639773/
https://www.ncbi.nlm.nih.gov/pubmed/34782793
http://dx.doi.org/10.1038/s41593-021-00944-z
Descripción
Sumario:Amyotrophic lateral sclerosis (ALS) is a devastating disorder in which motor neurons degenerate, the causes of which remain unclear. In particular, the basis for selective vulnerability of spinal motor neurons (sMNs) and resistance of ocular motor neurons (oMNs) to degeneration in ALS has yet to be elucidated. Here, we applied comparative multi-omics analysis of human induced pluripotent stem cell (hiPSC)-derived sMNs and oMNs to identify shared metabolic perturbations in inherited and sporadic ALS sMNs, revealing dysregulation in lipid metabolism and its related genes. Targeted metabolomics studies confirmed such findings in sMNs of 17 ALS (SOD1, C9ORF72, TDP43 and sporadic) hiPSC lines, identifying elevated levels of arachidonic acid (AA). Pharmacological reduction of AA levels was sufficient to reverse ALS-related phenotypes in both human sMNs and in vivo in Drosophila and SOD1(G93A) mouse models. Collectively, these findings pinpoint a catalytic step of lipid metabolism as a potential therapeutic target for ALS.